Purpose: To evaluate the properties of intraocular lens ERIFLEX 877 FAB, the manipulation during implantation and clinical outcomes after implantation of the new hydrophobic-hydrophilic intraocular lens in patients undergoing routine cataract surgery. Material and Methods: The study included 30 patients (38 eyes), mean age 71 ± 8 years (range 53–89 years) with senile cataract. After phacoemulsification intraocular lens ERIFLEX 877 FAB was implanted. Patients were evaluated at 3 months after surgery. We assessed the uncorrected visual acuity (UCVA) and best corrected visual acuity (BCVA), refraction, keratometry and the incidence of posterior capsule opacification (PCO - Posterior capsule opacification). Individual patient’s and surgeon’s satisfaction was also documented including manipulation during surgery. Results: Three months after surgery, the mean UCVA was 0.7 ± 0.2 and BCVA was 0.97 ± 0.16. PCO value was 0.15 ± 0.09, that means minimal incidence of PCO. Good UCVA and a minimal incidence of PCO have resulted in a high degree satisfaction of patients. Conclusion: The new hydrophobic-hydrophilic intraocular lens ERIFLEX 877 FAB could be easily implanted and after surgery shows a high degree of biocompatibility in patients undergoing routine cataract surgery.